Fallopian tube and ovarian cancers represent important gynecologic malignancies with peculiar origins and characteristics. Fallopian tube cancer, though rare, typically arises from the tubal epithelium and is increasingly considered a precursor to high-grade serous ovarian carcinoma. Ovarian cancer, notorious for late-stage diagnosis, stems from various cell types within the ovaries, with epithelial ovarian carcinoma being the most predominant. Risk factors include age, family history and genetic mutations (e.g., BRCA1/2 and homologous repair deficiency). Diagnostic challenges are intensified by non-specific symptoms and the lack of effective screening methods, leading to high mortality rates. Advances in molecular biology, targeted therapies, and genetic testing are critical for improving early detection, personalized treatment, and overall prognosis in these cancers.
This Special Issue welcomes contributions that improve our understanding of the etiology, pathogenesis, and progression of fallopian tube and ovarian cancers. We invite research on these malignancies' molecular and genetic substructures, including studies on hormonal influences, genetic mutations and epigenetic modifications. Contributions exploring innovative diagnostic techniques, early detection methods, and novel biomarkers are particularly encouraged, as they can improve early-stage diagnosis and patient outcomes. We also seek submissions on cutting-edge therapeutic approaches, including targeted therapies, immunotherapies, and personalized medicine strategies.
Potential areas of interest may include, but are not limited to:
● Molecular and Genetic Mechanisms
● Hormonal and Environmental Influences
● Diagnostic Innovations
● Therapeutic Strategies
● Personalized Medicine
● Epidemiology and Prevention
● Quality of Life and Survivorship
● Health Disparities
Even though abstract submission is not mandatory, we encourage all interested researchers to submit an abstract before submitting their manuscript. Abstracts do not have to coincide with the final abstract of the manuscripts. For authors, please review the journal's information regarding Author Guidelines and Article Processing Charges, or direct any questions to the Editorial Office: por@por-journal.com.
Keywords:
Gynecologic Oncology, Molecular Pathogenesis, Early Detection, Targeted Therapies, Personalized Medicine
Fallopian tube and ovarian cancers represent important gynecologic malignancies with peculiar origins and characteristics. Fallopian tube cancer, though rare, typically arises from the tubal epithelium and is increasingly considered a precursor to high-grade serous ovarian carcinoma. Ovarian cancer, notorious for late-stage diagnosis, stems from various cell types within the ovaries, with epithelial ovarian carcinoma being the most predominant. Risk factors include age, family history and genetic mutations (e.g., BRCA1/2 and homologous repair deficiency). Diagnostic challenges are intensified by non-specific symptoms and the lack of effective screening methods, leading to high mortality rates. Advances in molecular biology, targeted therapies, and genetic testing are critical for improving early detection, personalized treatment, and overall prognosis in these cancers.
This Special Issue welcomes contributions that improve our understanding of the etiology, pathogenesis, and progression of fallopian tube and ovarian cancers. We invite research on these malignancies' molecular and genetic substructures, including studies on hormonal influences, genetic mutations and epigenetic modifications. Contributions exploring innovative diagnostic techniques, early detection methods, and novel biomarkers are particularly encouraged, as they can improve early-stage diagnosis and patient outcomes. We also seek submissions on cutting-edge therapeutic approaches, including targeted therapies, immunotherapies, and personalized medicine strategies.
Potential areas of interest may include, but are not limited to:
● Molecular and Genetic Mechanisms
● Hormonal and Environmental Influences
● Diagnostic Innovations
● Therapeutic Strategies
● Personalized Medicine
● Epidemiology and Prevention
● Quality of Life and Survivorship
● Health Disparities
Even though abstract submission is not mandatory, we encourage all interested researchers to submit an abstract before submitting their manuscript. Abstracts do not have to coincide with the final abstract of the manuscripts.
For authors, please review the journal's information regarding Author Guidelines and Article Processing Charges, or direct any questions to the Editorial Office: por@por-journal.com.
Keywords:
Gynecologic Oncology, Molecular Pathogenesis, Early Detection, Targeted Therapies, Personalized Medicine